Investigating the anti-tumour efficacy and on target toxicity of gene-modified T cell therapy in vivo

来自癌症患者的白色血细胞可以在实验室中进行修饰，以对抗肿瘤。虽然这些细胞在返回给患者时可以诱导癌症消退，但这些细胞通常会导致相关的病理学。在这项研究中，我们建议充分研究这种类型的治疗在小鼠模型中介导抗肿瘤反应和潜在毒性的局限性，这些模型与人类环境密切相关。这些研究将为患者提供更有效的治疗方法。

White blood cells from cancer patients can be modified in the laboratory to react against tumours. Although these cells can induce cancer regression when given back to the patient, these cells can often cause associated pathology. In this study we propose to fully investigate the limits of this type of therapy for mediating anti-tumour responses and potential toxicity in mouse models that closely recapitulate the human setting. These studies will lead to a more effective therapy for patients.